6533b85bfe1ef96bd12bb66b
RESEARCH PRODUCT
Low molecular weight heparins as antineoplastic agents.
Sergio Siragusasubject
OncologyCancer Researchmedicine.medical_specialtyClinical Trials as Topicbusiness.industryCancerPatient survivalAntineoplastic AgentsGeneral MedicineHeparin Low-Molecular-WeightMalignancymedicine.diseaseSurvival RateLow molecular weight heparin cancer therapyOncologyInternal medicineNeoplasmsDrug DiscoveryAntithromboticmedicineHumansPharmacology (medical)In patientbusinessVenous thromboembolismdescription
There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.
year | journal | country | edition | language |
---|---|---|---|---|
2008-11-01 | Recent patents on anti-cancer drug discovery |